XML 17 R5.htm IDEA: XBRL DOCUMENT v3.20.4
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($)
Series F Preferred Stock [Member]
Preferred Stock [Member]
Series F Preferred Stock [Member]
Common Stock [Member]
Series F Preferred Stock [Member]
Additional Paid-in Capital [Member]
Series F Preferred Stock [Member]
Retained Earnings [Member]
Series F Preferred Stock [Member]
Preferred Stock [Member]
Common Stock [Member]
Additional Paid-in Capital [Member]
Retained Earnings [Member]
Total
BALANCE (in shares) at Jun. 30, 2019           3,594,981 1,753,808      
BALANCE at Jun. 30, 2019           $ 359 $ 176 $ 113,476,783 $ (106,389,500) $ 7,087,818
Stock-based compensation           165,171 165,171
Securities converted for common stock (in shares)           (443,833) 44,384      
Securities converted for common stock           $ (44) $ 5 39
Net loss           (4,929,030) (4,929,030)
BALANCE (in shares) at Sep. 30, 2019           3,151,148 1,798,192      
BALANCE at Sep. 30, 2019           $ 315 $ 181 113,641,993 (111,318,530) 2,323,959
BALANCE (in shares) at Jun. 30, 2019           3,594,981 1,753,808      
BALANCE at Jun. 30, 2019           $ 359 $ 176 113,476,783 (106,389,500) 7,087,818
Net loss                   (5,143,277)
BALANCE (in shares) at Dec. 31, 2019           10,215,845 2,073,307      
BALANCE at Dec. 31, 2019           $ 1,022 $ 209 128,621,786 (111,532,777) 17,090,240
BALANCE (in shares) at Sep. 30, 2019           3,151,148 1,798,192      
BALANCE at Sep. 30, 2019           $ 315 $ 181 113,641,993 (111,318,530) 2,323,959
Stock-based compensation           162,264 162,264
Securities converted for common stock (in shares)           (2,751,148) 275,115      
Securities converted for common stock           $ (275) $ 28 247
Net loss           (214,247) (214,247)
Issuance of stock (in shares) 10,000                
Issuance of stock $ 1 $ 5,249,483 $ 5,249,484          
Warrants issued in connection with the private placement           4,008,866 4,008,866
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics (in shares)           9,805,845      
Issuance of Series G preferred stock due to acquisition of the Cerecor portfolio of pediatrics therapeutics           $ 981 5,558,933 5,559,914
Issuance costs         $ (741,650)          
BALANCE (in shares) at Dec. 31, 2019           10,215,845 2,073,307      
BALANCE at Dec. 31, 2019           $ 1,022 $ 209 128,621,786 (111,532,777) 17,090,240
BALANCE (in shares) at Jun. 30, 2020           12,583,736      
BALANCE at Jun. 30, 2020           $ 1,259 215,024,216 (120,010,179) 95,015,296
Stock-based compensation           454,918 454,918
Net loss           (4,305,931) (4,305,931)
Issuance costs           (101,537) (101,537)
BALANCE (in shares) at Sep. 30, 2020           12,583,736      
BALANCE at Sep. 30, 2020           $ 1,259 215,377,597 (124,316,110) 91,062,746
BALANCE (in shares) at Jun. 30, 2020           12,583,736      
BALANCE at Jun. 30, 2020           $ 1,259 215,024,216 (120,010,179) 95,015,296
Net loss                   (13,831,224)
BALANCE (in shares) at Dec. 31, 2020           17,882,893      
BALANCE at Dec. 31, 2020           $ 1,788 246,532,284 (133,841,404) 112,692,668
BALANCE (in shares) at Sep. 30, 2020           12,583,736      
BALANCE at Sep. 30, 2020           $ 1,259 215,377,597 (124,316,110) 91,062,746
Stock-based compensation           508,059 508,059
Securities converted for common stock (in shares)           130,081      
Securities converted for common stock           $ 13 1,057,546 1,057,559
Net loss           (9,525,294) (9,525,294)
Issuance of stock (in shares)           5,169,076      
Issuance of stock           $ 516 28,316,928 28,317,444
Warrants issued in connection with the private placement           1,272,154 1,272,154
BALANCE (in shares) at Dec. 31, 2020           17,882,893      
BALANCE at Dec. 31, 2020           $ 1,788 $ 246,532,284 $ (133,841,404) $ 112,692,668